NanoViricides signs confidential disclosure agreement with Viroclinics NanoViricides has signed a “confidential disclosure agreement" with Viroclinics Biosciences, BV, a spinoff of the Department of Viroscience at the Erasmus Medical Centre in Rotterdam, the Netherlands. The agreement will allow the scientists at Viroclinics to develop a specific proposal for the testing of different nanoviricides , such as FluCide, against viruses of mutual interest to both organizations.
NanoViricides signs agreement with University of Wisconsin NanoViricides announced that it has entered into an agreement with the University of Wisconsin for the evaluation of its nanoviricides drug candidates in models of ocular herpes virus infections. The studies will be performed in the laboratory of Dr. Curtis Brandt, an expert in herpes simplex virus infections and in evaluating anti-viral agents. The Company has previously reported the successes of its nanoviricides drug candidates in pre-clinical studies of dermal herpes virus infections in mouse models. The studies in Dr. Brandt's laboratory will be critical in optimizing its anti-herpes drug candidates against ocular herpes virus infections. The goal of these studies will be to identify a drug development candidate as a treatment for ocular keratitis in humans caused by herpes simplex virus infections.